Ra Medical Systems, Inc. (NYSE: RMED) today announced the launch
of Pharos, Optimized, the next generation of Pharos excimer lasers,
designed to enhance physician and patient experience with faster
treatments for psoriasis, vitiligo, and atopic dermatitis;
extended peak performance; and a new ergonomic
handpiece for operator comfort and greater treatment site
visibility.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20190726005028/en/
Ra Medical Systems Launches Pharos,
Optimized Dermatology Excimer Laser (Photo: Business Wire)
"Pharos has added significant value to my dermatology practice
by quickly and painlessly treating stubborn conditions: psoriasis,
vitiligo, and atopic dermatitis,” said David J. Goldberg, MD.
“Faster treatments from the optimized Pharos laser will increase
patient satisfaction and motivate patients to complete the full
treatment regimen to achieve the best possible outcomes.” Dr.
Goldberg is a widely-published, world-renowned dermatologic laser
expert and is the director of Skin Laser & Surgery Specialists
of New York and New Jersey.
Psoriasis1, vitiligo2, and atopic dermatitis3 collectively
affect more than 25 million people in the United States. Pharos,
Optimized brings together 15 years of proven clinical success
treating these conditions with a user-centered design that reflects
customer experience with millions of procedures in the U.S. and 14
countries worldwide.
“The Pharos excimer laser is a workhorse in my practice,
treating chronic skin conditions that affect large patient
populations. With Pharos, I achieve clinical success clearing
plaques and re-pigmenting lesions that have not responded to other
treatments,” said Tien Q. Nguyen, MD. “Ra Medical Systems provides
excellent clinical and post-sales support with no recurring per
treatment expense to my practice.” Dr. Nguyen is the director of
First OC Dermatology in Irvine and Fountain Valley, CA.
Pharos is the only excimer laser to feature integrated
adjustable aiming and laser beams to deliver precisely targeted
treatments that spare healthy tissue. The laser’s small footprint
enables it to fit into any treatment room, saving valuable floor
space.
“The optimized Pharos is a next generation laser that delivers
what dermatologists have been asking for: faster treatments for
psoriasis, vitiligo, and atopic dermatitis and an upgraded user and
patient experience,” said Dean Irwin, CEO, Ra Medical Systems,
Inc.
Pharos, Optimized will make its debut at the 2019 American
Academy of Dermatology Summer Meeting, which takes place from July
25-28, 2019 at the Hilton Midtown in New York, NY. Visit Ra
Medical’s Booth No. 830 at the AAD or click to watch the
video to learn more.
1 https://www.psoriasis.org/content/statistics 2
https://www.aad.org/File%20Library/Top%20navigation/About/Burden%20of%20Skin%20Disease/Vitiligo.pdf
3 https://nationaleczema.org/research/eczema-facts/
About Ra Medical Systems
Ra Medical Systems is a commercial medical device company
developing and marketing innovative excimer laser systems for the
treatment of vascular and dermatologic diseases. DABRA launched in
2017 for the endovascular treatment of blockages resulting from
lower extremity vascular disease. Pharos launched in 2004 for the
treatment of dermatological disorders including psoriasis,
vitiligo, and atopic dermatitis. DABRA and Pharos are based on Ra
Medical’s core excimer laser technology platform that produces 308
nanometer light, a UVB wavelength that studies have demonstrated
increases T-cell apoptosis, or cell death, which may produce a
beneficial, targeted immunosuppressive effect. Ra Medical
manufactures DABRA and Pharos excimer lasers and catheters in a
32,000-square-foot facility located in Carlsbad, California. The
vertically integrated facility is ISO 13485 certified and is
licensed by the state of California to manufacture sterile,
single-use catheters in controlled environments.
Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements generally relate to future events
or Ra Medical's future financial or operating performance. In some
cases, you can identify forward-looking statements because they
contain words such as "may," "will," "should," "expects," "plans,"
"anticipates," "could," "intends," "target," "projects,"
"contemplates," "believes," "estimates," "predicts," "potential" or
"continue" or the negative of these words or other similar terms or
expressions that concern Ra Medical's future expectations,
strategy, plans or intentions. Forward-looking statements in this
press release include, but are not limited to, statements regarding
the potential benefits to patients and physicians using the DABRA
catheter and laser system. Ra Medical's expectations and beliefs
regarding these matters may not materialize, and actual results in
future periods are subject to risks and uncertainties that could
cause actual results to differ materially from those projected or
implied by such forward-looking statements. The potential risks and
uncertainties which contribute to the uncertain nature of these
statements include, among others, risks associated with acceptance
of DABRA and Pharos and procedures performed using such devices by
physicians, payors, and other third parties; development and
acceptance of new products or product enhancements; clinical and
statistical verification of the benefits achieved via the use of Ra
Medical’s products; the Company’s ability to effectually manage
inventory; Ra Medical’s ability to recruit and retain management
and key personnel; Ra Medical’s need to comply with complex and
evolving laws and regulations; intense and increasing competition
and consolidation in Ra Medical’s industry; the impact of rapid
technological change; costs and adverse results in any ongoing or
future legal proceedings; adverse outcome of regulatory
inspections; and the other risks and uncertainties described in Ra
Medical’s news releases and filings with the Securities and
Exchange Commission. Information on these and additional risks,
uncertainties, and other information affecting Ra Medical's
business and operating results is contained in Ra Medical’s
quarterly report on Form 10-Q for the quarter ended March 31, 2019
and in its other filings with the Securities and Exchange
Commission. The forward-looking statements in this press release
are based on information available to Ra Medical as of the date
hereof, and Ra Medical disclaims any obligation to update any
forward-looking statements, except as required by law.
Ra Medical investors and others should note that we announce
material information to the public about the Company through a
variety of means, including our website (www.ramed.com), our
investor relations website (https://ir.ramed.com/), press releases,
SEC filings, and public conference calls in order to achieve broad,
non-exclusionary distribution of information to the public and to
comply with our disclosure obligations under Regulation FD. We
encourage our investors and others to monitor and review the
information we make public in these locations as such information
could be deemed to be material information. Please note that this
list may be updated from time to time.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190726005028/en/
Media Contacts David Schemelia / Lisa Lipson KCSA
Strategic Communications 212.896.1242 / 508.843.6428
dschemelia@kcsa.com / llipson@kcsa.com
Investor Contact Jeffrey Kraws President, Ra Medical
Systems 760.707.7516 investorrelations@ramed.com
Ra Medical Systems (NYSE:RMED)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ra Medical Systems (NYSE:RMED)
Historical Stock Chart
From Apr 2023 to Apr 2024